Page last updated: 2024-08-23

alovudine and Osteosarcoma

alovudine has been researched along with Osteosarcoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bradshaw, TJ; Forrest, LJ; Jallow, N; Jeraj, R; Yip, S	1
Boerman, OC; Fleuren, ED; Flucke, UE; Franssen, GM; Houghton, PJ; Oyen, WJ; Roeffen, MH; van der Graaf, WT; Versleijen-Jonkers, YM	1
Benz, MR; Czernin, J; Eilber, FC; Federman, N; Tap, WD; Tchekmedyian, N	1

Reviews

1 review(s) available for alovudine and Osteosarcoma

Article	Year
Utilization of positron emission tomography in the management of patients with sarcoma. Current opinion in oncology, 2009, Volume: 21, Issue:4 Topics: Bone Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Osteosarcoma; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoma	2009

Other Studies

2 other study(ies) available for alovudine and Osteosarcoma

Article	Year
Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy. International journal of radiation oncology, biology, physics, 2014, Jun-01, Volume: 89, Issue:2 Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Proliferation; Chondrosarcoma; Coordination Complexes; Dideoxynucleosides; Dog Diseases; Dogs; Dose Fractionation, Radiation; Multimodal Imaging; Nose Neoplasms; Organometallic Compounds; Osteosarcoma; Paranasal Sinus Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Thiosemicarbazones; Tomography, X-Ray Computed	2014
Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. International journal of cancer, 2014, Dec-15, Volume: 135, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2014

Article

Year

Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.

International journal of radiation oncology, biology, physics, 2014, Jun-01, Volume: 89, Issue:2

Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Proliferation; Chondrosarcoma; Coordination Complexes; Dideoxynucleosides; Dog Diseases; Dogs; Dose Fractionation, Radiation; Multimodal Imaging; Nose Neoplasms; Organometallic Compounds; Osteosarcoma; Paranasal Sinus Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Thiosemicarbazones; Tomography, X-Ray Computed

2014

Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.

International journal of cancer, 2014, Dec-15, Volume: 135, Issue:12

Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Positron-Emission Tomography; Protein Kinase Inhibitors; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2014